Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (FRA:I54)

Market Cap	4.24B +311.9%
Revenue (ttm)	218.96M +42.7%
Net Income	47.20M +177.0%
EPS	0.11 +171.8%
Shares Out	n/a
PE Ratio	40.75
Forward PE	98.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	4.800
Previous Close	4.560
Day's Range	4.560 - 4.800
52-Week Range	2.545 - 8.900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About FRA:I54

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,922
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I54

Financial Performance

In 2025, FRA:I54's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 24, 2026

Data Sources Report a data error